My watch list
my.chemeurope.com  
Login  

12 Current news about the topic target validation

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

Merck Signs Strategic Alliance With Archemix

13-Jun-2007

Merck KGaA announced that it has formed a multi-year strategic alliance between its Merck Serono division and Archemix Corp. of Cambridge, Massachusetts, to discover, develop and commercialize first-in-class aptamer therapeutics with a primary focus on the treatment of cancer. Additional areas of ...

more

Strategic Analysis of the World Oligonucleotides Markets

Innovation Integral to Increased Adoption of Oligonucleotide Technologies

01-Aug-2004

London, UK. Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan (http://pharma.frost.com) estimates that the total global market for oligonucleotides is likely to grow from ...

more

Novartis and Compugen expand collaboration for identification, prioritization and validation of new drug targets

06-Sep-2002

Basel / Tel Aviv, 4 September 2002 - Novartis and Compugen today announced the expansion of their multimillion-dollar collaboration, for the accelerated identification of drug targets, to include target validation. Under the expanded agreement, the two companies will collaborate on the research ...

more

Myriad Genetics and Abbott Laboratories Form Drug Discovery Collaboration

- Alliance to Focus on Discovery of Drugs to Treat Depression -

13-Mar-2002

SALT LAKE CITY, Mar 12, 2002 Myriad Genetics, Inc., announced today that it has formed a drug discovery collaboration with Abbott Laboratories to identify novel genes and drug targets for the diagnosis and treatment of depression. The collaboration will merge Myriad's integrated drug target ...

more

Pharmagene signs new contract with Astrazeneca

15-Feb-2002

Royston, UK, 13 February 2002 - Pharmagene plc (LSE: PGN announced today that it has entered into an agreement with AstraZeneca UK Limited to help AstraZeneca identify drug targets as part of its drug discovery programmes. Financial details have not been disclosed. Pharmagene will utilise its ...

more

Bayer starts research collaboration with Italian biotech company in the field of post-genomics

Bayer's Italian research unit to be integrated into newly founded biotech company Axxam

19-Nov-2001

Leverkusen – Bayer has entered a collaboration with Axxam S.r.l., a newly formed Italian biotechnology company, in the field of post-genomics with the objective of developing several technology platforms for modern drug discovery. The results of genome research are thus used to develop biological ...

more

Lilly and Isis Pharmaceuticals Announce Strategic Alliance

23-Aug-2001

Eli Lilly and Company (NYSE: LLY) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) announced today that they have entered into a strategic alliance that includes the license of Isis' novel antisense cancer compound and the formation of a broad collaboration to discover antisense drugs. The ...

more

Bristol-Myers Squibb Selects Pharmaceutically Relevant Targets For Drug Discovery From Lexicon's LexVision™ Database

09-Aug-2001

Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that the Bristol-Myers Squibb Company (NYSE:BMY) has selected certain drug targets of potential pharmaceutical relevance contained in LexVision for use in its drug discovery programs. "Bristol-Myers Squibb’s request for the in ...

more

Bristol-Myers Squibb And Exelixis Enter Pioneering Cancer-Fighting Alliance

Drug Discovery Collaboration Targets New Frontier of Tumor Suppressor Genes

19-Jul-2001

Bristol- Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced a broad collaboration and licensing agreement to create a new generation of cancer drugs that selectively destroy cancers that harbor defects in tumor suppressor gene pathways. Tumor suppression ...

more

Myriad Genetics Discovers High Cholesterol Gene

06-Jun-2001

Myriad Genetics, Inc. (Nasdaq: MYGN), has discovered a human gene responsible for high total cholesterol and low HDL (also known as "good cholesterol"), in individuals with early age myocardial infarction. The research shows that the gene's protein product is produced in abnormal amounts in ...

more

Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE